ArticleBMC public health2026
Medication adherence and associated factors in patients with chronic hepatitis B in Zhejiang Province, Eastern China.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic hepatitis B (CHB) remains a significant public health burden in China. Sustained adherence to long-term nucleos(t)ide analogues (NAs) therapy is crucial for preventing disease progression, but large-scale evidence on adherence and its influencing factors remains limited, particularly in the context of evolving healthcare policies.
methodsA cross-sectional study was conducted from June to August 2025 in Zhejiang Province, using phased stratified sampling. Data were collected through structured, interviewer-administered questionnaires, including the validated 8-item Morisky Medication Adherence Scale (MMAS-8). Mann-Whitney U and Kruskal-Wallis tests were used to compare ordinal variables across categories of categorical variables. A partial proportional odds model with city as a fixed effect was used to identify factors associated with adherence. Sensitivity analyses using linear mixed models with MMAS-8 scores as a continuous outcome were performed.
resultsAmong the 907 CHB patients, the median MMAS-8 score was 7.75 (IQR: 6.75-8), with 46.0% classified as high adherence, 34.5% as medium adherence, and 19.5% as low adherence. In the adjusted partial proportional odds model, older age (50–59 years: OR = 1.73, 95% CI: 1.12–2.67; ≥60 years: OR = 1.81, 95% CI: 1.14–2.89), having a fixed dosing time (OR = 4.01, 95% CI: 2.13–7.55), and attending regular follow-up (OR = 1.98, 95% CI: 1.35–2.92) were associated with higher adherence. Conversely, taking two or more additional daily prescription medications (OR = 0.61, 95% CI: 0.37–0.99) and an annual NAs cost of 300–599 RMB (OR = 0.59, 95% CI: 0.42–0.83) were associated with lower adherence. Notably, no patient cited unaffordable medication costs as a reason for missed doses. Forgetfulness (58.7%) and perceived symptomatic improvement (21.8%) were the most frequently reported barriers.
conclusionsAdherence to NAs therapy among CHB patients in Zhejiang was generally favorable, with most patients classified as having medium or high adherence. Adherence was positively associated with age, fixed dosing time, and regular clinical follow-up, and negatively associated with polypharmacy and specific out-of-pocket costs. Interventions should focus on younger patients, simplify medication regimens, provide behavioral support, and reinforce patient education on the necessity of lifelong therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.